Month: November 2025

TOKYO, Nov 27, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Electric Building Solutions Corporation (MEBS, Head Office: Chiyoda-Ku, Tokyo; President: Iwao Oda) today announced that Mitsubishi Electric de Mexico S.A. de C.V. (MELMEX), which is responsible for elevator and escalator sales in Mexico, completed the renewal of one of the spiral escalators at the Liverpool department store in the Centro Santa Fe shopping mall in Santa Fe, Mexico on October 15. This project was the first-ever spiral escalator renewal project conducted anywhere in the world.Spiral escalator after the renewalSpiral escalators, which are curved escalators that trace an arc, are manufactured exclusively by MEBS. The unit that was renewed this time is one of two spiral escalators in Mexico delivered by the company in 1992 that remain in operation today. Elevators and escalators undergo continuous and appropriate maintenance in order to sustain and restore their functionality. However, the risks associated with deterioration through aging and the number of discontinued or unavailable parts increase over time. Through this renewal, the company replaced key components at an optimal timing, enhancing the escalator’s safety, reliability, and comfort. In addition, by applying new features and designs, the project improved its energy efficiency, and aesthetic value. The company will pass on the insights and know-how gained during this renewal to the next generation and continue to respond effectively to customers’ future needs for spiral escalator renewals.Construction and Features of the Renewed Product1) The world’s first ever renewal of a spiral escalator, contributing to the product’s continued safe and secure operation- The team carried out the world’s first renewal of a spiral escalator, a product manufactured exclusively by MEBS.- Several major parts (the control panel, drive unit, safety devices, etc.) were replaced to ensure the continued safe and secure operation of this spiral escalator, which is a central feature of the building.2) Achieving improved energy efficiency, and aesthetic appearance by applying the latest functions and design- An automatic operation stationary in stand-by function has been newly introduced. A sensor detects the presence of escalator users and automatically stops operation when no users are detected. This reduces energy consumption when the escalator is unoccupied.- By replacing the existing polycarbonate interior panels with glass panels, the renewal will reduce aging-related effects such as photodegradation, which is a characteristic of plastic materials, and improve the escalator’s aesthetic appearance.- By enhancing the escalator’s energy conservation, and aesthetic appearance, the renewal will contribute to increasing the value of the customer’s building.3) Achieving a safe and high-quality renewal by overcoming construction conditions and structural issues with highly skilled techniques- Although the facility remained in operation and the working space was limited, which made it difficult to secure room for removing the existing components, the work was completed by repeatedly repositioning and reconfiguring the on-site lifting crane and gantry**.- During the installation of the interior panels and decorative parts, the spiral escalator's unique curved design makes it easy for slippage and gaps to occur. To overcome this problem, skilled workers drew on their experience to make fine adjustments down to the millimeter, such as cutting parts on site.- Through this renewal work, the company has strengthened its ability to meet customers’ future renewal needs by reliably handing down to and sharing with the next generation the advanced, highly specialized technologies and skills related to renewal of spiral escalators.Product SpecificationsProductMain replacement partsNo. of unitsManufacturerSpiral EscalatorControl Panel, Drive Unit, Safety Devices, Handrails, Steps, Interior Panels1 unitINZAZWA Building Systems Works* The panel shown here differs from the panels delivered for the current project.** Unlike conventional construction or overhead cranes, this is a self-supporting, lightweight crane device designed for handling light loads. It features an aluminum frame for easy installation and relocation, and can be operated without relying on the building’s structural elements.Future DevelopmentSince MEBS developed the world’s first spiral escalator in 1985, MEBS has manufactured a total of 111 units. Some of these existing spiral escalators are now 30 to 40 years old, and a certain level of demand for renewing these units to continue in future years. Spiral escalators, in particular, require extremely specialized technology and expertise from design to manufacture and installation due to their unique curved structure. In addition, unlike new spiral escalator installations conducted in the past, this renewal project was the company’s first attempt to dismantle, install, and adjust existing parts that can still be used, such as the trusses that form the escalator’s framework. In this project, a skilled engineer who has successfully installed spiral escalators in Japan and all over the world took the lead and completed the work while handing down his or her expertise to the next generation. MEBS will continue to provide its one-of-a-kind spiral escalators together with high-quality maintenance and renewal services so that these machines can continue to be used safely and comfortably around the world.Overview of MELMEXCompany NameMitsubishi Electric de Mexico S.A. de C.V.LocationState of Mexico, United Mexican StatesOwnershipMitsubishi Electric Corporation: 86.15%Mitsubishi Electric Building Solutions Corporation: 13.85%EstablishedApril 1976BusinessSales, manufacture, installation, and maintenance of elevators and escalators About Mitsubishi Electric Building Solutions CorporationMitsubishi Electric Building Solutions Corporation is a consolidated subsidiary of Mitsubishi Electric Corporation established in April 2022 that conducts a comprehensive range of operations in the building systems business, from development and manufacturing to maintenance and renewal. As a building solutions provider, we support the economic and social infrastructure through one-stop integrated solutions that combine a wide range of building-related products and services, including elevators, escalators, air conditioning and refrigeration equipment, and building systems, as well as with our extensive experience in building operation and management, and advanced digital technology. From buildings to building complexes and even entire cities, we contribute to enriching human life in buildings and urban spaces by solving a wide variety of issues that are closely linked to people and society, with the ultimate aim of realizing smart cities. For more information, please visit www.mebs.com/ Customer InquiriesCorporate Planning Department, Global Business GroupMitsubishi Electric Building Solutions Corporationbod.inquiry@rk.MitsubishiElectric.co.jp Media InquiriesCorporate Communication DivisionMitsubishi Electric Building Solutions Corporation A_mebs_press@meltec.co.jp Press Release: http://www.acnnewswire.com/docs/files/20251127.pdf Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and CAMBRIDGE, Mass., Nov. 26, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: HaruoNaito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector(SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment(MCI) or mild dementia stage of disease (collectively referred to as early AD). Upon acceptance of the sBLA, the FDA will set a Prescription Drug User Fee Act (PDUFA) action date (target date for review completion). The sBLA is supported by data evaluating subcutaneous (SC) administration of lecanemab across arange of doses and as part of sub-studies within the Phase 3 Clarity AD open-label extension (OLE)following the 18-month core study in individuals with early AD. Data show that once-weekly administration of the 500 mg of SC-AI achieved equivalent exposure to once every two weeks intravenous (IV) administration and similar clinical and biomarker benefits. Subcutaneous administration demonstrated a safety profile similar to IV administration, with less than 2% incidence ofsystemic injection/infusion-related reactions.Should the FDA approve the LEQEMBI IQLIK 500 mg SC dosing regimen (two 250 mg injections), the autoinjector could be used to administer a once- weekly starting dose, as an alternative to the current bi-weekly (every two weeks) intravenous (IV) dosing. This would enable patients and care partners to choose SC administration at home for both initial treatment and the currently approved maintenance therapy, offering the option of SC or IV administration throughout the entire treatment journey. The injection time for each LEQEMBI IQLIK autoinjector takes approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion and nurse monitoring, while streamlining the overall AD treatment pathway.AD is a progressive, relentless disease, with amyloid beta (Aβ) and tau as hallmarks, that is caused by a continuous underlying neurotoxic process driven by protofibrils* that begins before amyloid plaqueaccumulation and continues after plaque removal.1,2,3 Only LEQEMBI fights AD in two ways – targetingboth protofibrils and amyloid plaque, which can impact tau downstream. LEQEMBI is currently approved in 51 countries and regions and is under regulatory review in 9 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance dosing after 18 months of IV treatment every two weeks.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202581pdf.pdf Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com